Triiodothyronine may be possibly associated with better cognitive function and less extrapyramidal symptoms in chronic schizophrenia

Ichioka, Shugo; Terao, Takeshi; Hoaki, Nobuhiko; Matsushita, Takuo; Hoaki, Takayuki

doi:10.1016/j.pnpbp.2012.06.008

Cited by 23 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A critical evaluation of those results, however, highlights the possibility of a beta-error in using subgroups with small sample sizes. Similarly, an investigation of patients of both sexes diagnosed with chronic schizophrenia and actively treated with antipsychotics found a link between prolactin and cognitive function; nevertheless, it could not demonstrate a direct association using the cognitive parameters measured with the Mini-Mental test ( Ichioka et al, 2012 ).…”

Section: Cognition and Prolactinmentioning

confidence: 97%

The search for new biomarkers for cognition in schizophrenia

Penadés

García-Rizo

Bioque

et al. 2015

Schizophrenia Research: Cognition

View full text Add to dashboard Cite

The search for biomarkers in cognition has been the focus of a large part of the research on patients suffering from schizophrenia. The scientific literature is heterogeneous, and few studies establishing an integrative model of pathogenesis and therapeutic response are available in this field. In this review, we aimed to summarize three essential aspects correlated with cognitive performance: 1) the relationship between inflammation and cognition in schizophrenia, 2) the role of prolactin in cognition, and 3) the association between cognition and neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF).Several studies support the association of inflammatory markers with cognitive status in schizophrenia. In recent decades, the development of effective therapies for cognitive impairment in schizophrenia has focused on the search for anti-inflammatory and immunomodulatory medications. Conversely, the implications of prolactin and its functions in cognition, the transition to psychosis and the diagnosis and prognosis of schizophrenia have been established independent of antipsychotic treatment. With regard to neurotrophic factors, a recent study has correlated BDNF levels with cognitive recovery in schizophrenic patients treated with cognitive remediation.We conclude that although there is a diversity of biomarkers focused on cognitive function in schizophrenia, BDNF is the biomarker that has accumulated the vast majority of evidence in the current literature.

show abstract

Section: Cognition and Prolactinmentioning

confidence: 97%

The search for new biomarkers for cognition in schizophrenia

Penadés

García-Rizo

Bioque

et al. 2015

Schizophrenia Research: Cognition

View full text Add to dashboard Cite

show abstract

“…Patients with schizophrenia may self-regulate their hormone levels in the HPTA and HPAA under chronic stress exposure (15). For example, free triiodothyronine (FT3) level is positively associated with cognitive function (16), while cortisol (COR) responses to stress (17). In terms of thyroid hormonal components, conjugated thyroxine is the storage and transportation form of the hormone, while FT4 is the active component.…”

mentioning

confidence: 99%

Functional Status of Hypothalamic–Pituitary–Thyroid and Hypothalamic–Pituitary–Adrenal Axes in Hospitalized Schizophrenics in Shanghai

Zhu

Tao

et al. 2020

Front. Psychiatry

View full text Add to dashboard Cite

Objective: Neuroendocrine dysfunction is related to the pathogenesis of mental disorders, but conclusions from clinical research lack consistency. We aimed to investigate the neuroendocrinal pathophysiology and its correlation with clinical symptoms in patients with schizophrenia. Methods:The present cross-sectional study included 486 inpatients with schizophrenia admitted at a psychiatric hospital in Shanghai within one year, and 154 healthy controls (HC) matched on age and gender. The serum hemoconcentrations of thyroid-stimulating hormone (TSH), total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine (FT3), free thyroxine (FT4), adrenocorticotrophic hormone (ACTH), and cortisol (COR) were measured via electrochemical luminescence immunoassay. Pathophysiological conversions of neuroendocrine were then associated with gender, age, age at onset, antipsychotic treatment using hierarchical multiple linear regression.Results: When compared to HC, the schizophrenia group showed elevated ACTH and COR levels and decreased TT3 and TT4 levels (p's < 0.05). First-episode patients showed lower TSH and higher FT3 and FT4 (p's < 0.05) compared to recurrent patients. Female patients showed higher TSH and lower TT3, FT3, and ACTH levels (p's < 0.05) compared to males. We observed the area under the curve (AUC) of the predictive model to distinguish between schizophrenia and HC to be 0.737 among total samples and between first-episode and recurrent schizophrenia to be 0.890 among subgroups.Conclusions: Decreased TT3 and TT4 and elevated ACTH and COR levels appear to be associated with schizophrenia symptoms. The chronic recurrent trait of schizophrenia Frontiers in Psychiatry | www.frontiersin.org

show abstract

“…These abnormalities may disappear following successful treatment of schizophrenia and may also have a correlation with treatment response to antipsychotics [ 16 ]. For instance, it has been observed that higher T3 serum levels in patients with chronic schizophrenia are related to their better cognitive functions and lower extrapyramidal drug side effects [ 17 ]. It has also been seen that high basal TSH is associated with poorer response and blunted TSH response to thyrotropin releasing hormone (TRH) and a high level of T4 before treatment with better response to treatment [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

Levothyroxine Augmentation in Clozapine Resistant Schizophrenia: A Case Report and Review

Seddigh

Azarnik

Keshavarz-Akhlaghi

2015

Case Reports in Psychiatry

View full text Add to dashboard Cite

There are many reports that show different thyroid abnormalities in schizophrenia without clear establishment of their role in etiology and treatment outcome of schizophrenia. Among these reports, there are only a few that consider a role for thyroid hormones as augmenting agents in the treatment with antipsychotic drugs. This case report outlines symptom subsidence of a patient with clozapine refractory paranoid schizophrenia and normal thyroid function who added levothyroxine to clozapine and found that symptoms of psychosis returned once levothyroxine was discontinued. Although this observation needs to be confirmed in controlled clinical trials, we aimed to discuss possible hypothesized mechanisms underlying this observation.

show abstract

Triiodothyronine may be possibly associated with better cognitive function and less extrapyramidal symptoms in chronic schizophrenia

Cited by 23 publications

References 16 publications

The search for new biomarkers for cognition in schizophrenia

The search for new biomarkers for cognition in schizophrenia

Functional Status of Hypothalamic–Pituitary–Thyroid and Hypothalamic–Pituitary–Adrenal Axes in Hospitalized Schizophrenics in Shanghai

Levothyroxine Augmentation in Clozapine Resistant Schizophrenia: A Case Report and Review

Contact Info

Product

Resources

About